文献速递类风湿关节炎脊柱关节炎

在单份MDHAQ中通过FAST4和/或MDS2筛查纤维肌痛和/或抑郁阳性的炎症性关节炎患者,患者总体评估可升高多达10分中的5分

Patient global assessment is elevated by up to 5 of 10 units in patients with inflammatory arthritis who screen positive for fibromyalgia (by FAST4) and/or depression (by MDS2) on a single MDHAQ.
PubMed 文献 · Semin Arthritis Rheum · 2022-12-09

在巴塞罗那、芝加哥和悉尼常规诊疗的393例类风湿关节炎(RA)和175例脊柱关节炎(SpA)患者中,完成2页多维健康评估问卷(MDHAQ)。FAST4和MDS2筛查均阴性的患者中位PATGL为2.0-3.0,而FAST4和/或MDS2筛查阳性的患者中位PATGL升高至5.5-8.0,提示纤维肌痛和/或抑郁可独立于炎症活动升高PATGL。

要点

  • 在常规诊疗的RA和SpA患者中,FAST4和/或MDS2筛查阳性者占41%。
  • FAST4-、MDS2-患者中位PATGL为2.0-3.0(305例,58.9%)。
  • FAST4+和/或MDS2+患者中位PATGL升高至5.5-8.0。

核心结论

  • 根据单份MDHAQ中纤维肌痛和/或抑郁筛查阴性 vs 阳性,中位0-10分PATGL从2-3/10变化至5.5-8/10。

研究设计与样本

  • 在巴塞罗那、芝加哥和悉尼常规诊疗中,393例RA和175例SpA患者完成2页MDHAQ,耗时5-10分钟。
  • MDHAQ包含PATGL、RAPID3、FAST4(0-4分纤维肌痛评估筛查工具)和MDS2(0-2分MDHAQ抑郁筛查)。
  • 采用中位数和中位数回归比较各诊断、各中心及汇总数据中FAST4阳性(+)vs 阴性(-)和/或MDS2+ vs MDS2-患者的PATGL。

主要发现

  • 393例RA和175例SpA患者的中位PATGL为5.0。
  • 305例(58.9%)FAST4-、MDS2-患者的中位PATGL为2.0-3.0。
  • 71例(13.7%)FAST4-、MDS2+患者的中位PATGL为5.5-6.0。
  • 50例(9.7%)FAST4+、MDS2-患者的中位PATGL为7.0-7.5。
  • 92例(17.8%)FAST4+、MDS2+患者的中位PATGL为7.0-8.0;FAST4和/或MDS2筛查阳性者占41%。

关键数值与推荐

  • FAST4-、MDS2-患者中位PATGL为2.0-3.0(305例,58.9%)。
  • FAST4-、MDS2+患者中位PATGL为5.5-6.0(71例,13.7%)。
  • FAST4+、MDS2-患者中位PATGL为7.0-7.5(50例,9.7%)。
  • FAST4+、MDS2+患者中位PATGL为7.0-8.0(92例,17.8%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patient global assessment (PATGL) is a component of rheumatoid arthritis (RA) and spondyloarthritis (SpA) activity indices, reflecting inflammation in selected clinical trial patients. In routine care, PATGL often may be elevated independently of inflammatory activity by fibromyalgia (FM) and/or depression, leading to complexities in interpretation. A feasible method to screen for FM and/or depression could help to clarify interpretation of high PATGL and index scores, including explanation of apparent limited responses to anti-inflammatory therapies. PATIENTS AND METHODS: Patients with RA or SpA in routine care in Barcelona, Chicago, and Sydney complete a 2-page multidimensional health assessment questionnaire (MDHAQ) in 5-10 min. The MDHAQ includes PATGL and three indices, RAPID3 (routine assessment of patient index data) to assess clinical status, FAST4 (0-4 fibromyalgia assessment screening tool) and MDS2 (0-2 MDHAQ depression screen). PATGL was compared for each diagnosis at each site and pooled data in FAST4 positive (+) vs negative (-) and/or MDS2+ vs MDS2- patients using medians and median regressions. RESULTS: Median PATGL was 5.0 in 393 RA and 175 SpA patients; 2.0-3.0 in 305 (58.9%) FAST4-,MDS2- patients, 5.5-6.0 in 71 (13.7%) FAST4-,MDS2+ patients, 7.0-7.5 in 50 (9.7%) FAST4+,MDS2- patients, and 7.0-8.0 in 92 (17.8%) FAST4+,MDS2+ patients. Positive FAST4 and/or MDS2 screens were seen in 41% of patients. Results were similar in RA and SpA at 3 settings on 3 continents. CONCLUSION: Median 0-10 PATGL varied from 2-3/10 to 5.5-8/10, according to negative vs positive screening for FM and/or depression on a single MDHAQ for busy clinical settings.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Schmukler J, Li T, Gibson KA, et al. Patient global assessment is elevated by up to 5 of 10 units in patients with inflammatory arthritis who screen positive for fibromyalgia (by FAST4) and/or depression (by MDS2) on a single MDHAQ. Semin Arthritis Rheum. 2022. PMID: 36586208. doi:10.1016/j.semarthrit.2022.152151

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。